LSP in €42m series-B for Nouscom

New investor Abingworth led the round, in which 5am Ventures (also a new investor) and existing investor Versant Ventures also took part.

The fresh capital will be used to advance the Nous-209 programme, an off-the-shelf cancer vaccine, into phase-I/II clinical trials. The programme is based on Nouscom's Evovax platform.

The company will also continue with development of Nous-100-PV, a programme based on its Endovax platform that is still in the discovery phase.

Previous funding
LSP and Versant led a €12m series-A for Nouscom in May 2016.

Company
Based in Basel, Nouscom's technology focuses on viral vectors and oncolytic viruses, which infect and kill tumor cells and stimulate an immune response against cancer cells throughout the body. It has two product candidates, the Endovax and Exovax programmes. Endovax is an antigenless vaccine based on oncolytic viruses capable of infecting and replicating only in cancer cells. Exovax is a personalised patient-specific vaccine.

People
Nouscom – Alfredo Nicosia (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Germany
• Venture
• Life Science Partners